LOGIN
Zoledronic acid has no continued benefit beyond 6 years for osteoporosis
December 2015
Zoledronic acid has no continued benefit beyond 6 years for osteoporosis
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
J Bone Miner Res. 2015 May;30(5):934-44.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
One hundred and ninety patients were randomized to receive either continued zolderonic acid (ZOL) treatment or were switched to a placebo after six years of ZOL treatment for osteoporosis. Patients received treatment for an additional 3 years to determine continued efficacy and safety of ZOL. Results found that there was no significant benefit to continued ZOL treatment. Additionally, there was a ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.